It is easy to find that the effect of cytokines targeting drugs against IL-1 in preventing MAS in COVID-19 is different from that in patients with MAS alone, which may be related to the difference between MAS and MAS in COVID-19 mentioned above. The gene discussed is IL1B; the disease is macrophage activation syndrome.